Kamada launches two biosimilar products in Israel

Kamada launched two biosimilars in Israel: Ustekinumab-Kamada and Enoxaparin-Kamada, joining two biosimilars launched there over the past two years; all four are approved as interchangeable with their reference biologics. The company expects biosimilar sales of approximately $4 million in 2026 and $10 million in 2028, and projects at least 12 marketed products and $20 million-$25 million in annual revenue by 2030.

Analysis

The read-through is strategically positive but the near-term earnings signal is limited: the value driver is not the launch count, but whether Kamada can secure reimbursement and formulary access, convert approvals into repeat prescriptions, and retain attractive economics after licensing costs and tender discounts. Interchangeability may lower prescribing friction, but it does not ensure substitution or share gains against originators and other biosimilar suppliers.

The projected ramp is a useful execution test, not yet a basis for underwriting a material change in consolidated value. The article gives no license economics, product-level uptake, gross-to-net pricing, or comparison with Kamada’s existing revenue and cash generation. Israeli launches also do not establish access across the wider MENA region, where regulatory and procurement pathways may differ. Over 6–18 months, a broader portfolio could diversify commercial growth, but also adds launch, inventory, and partner-dependence risk.

The contrarian point: investors may overvalue the number of products and underweight the small initial sales base and uncertain conversion from launch to durable share. Conversely, if early uptake is strong, the pipeline of licensed products could make the current revenue projections conservative; verify sell-through and contract economics before changing estimates. Near-term catalysts are reimbursement/tender wins and first sales disclosures; the thesis weakens if availability fails to translate into reported revenue or management lowers portfolio targets.

Key Decisions for Investors

• No immediate directional trade on the announcement alone. Treat KMDA as a watch item until reported biosimilar sales can be compared with the company’s stated ramp and with consolidated revenue and cash generation.
• For the next 1–3 months, monitor reimbursement and tender access, product-level availability, and any evidence of repeat orders. Confirm whether reported sales are sell-through or distributor shipments and whether launch costs or licensing terms constrain contribution.
• Consider a staged long only after evidence of uptake and economics supports the 2026–2028 trajectory; cap the thesis around the biosimilar segment rather than extrapolating it to the whole company. Reassess if guidance is cut, launch timing slips, or sales growth comes with materially weaker economics than expected.
• Do not short originators solely on this news: no market-share displacement or revenue exposure is quantified. A competitor trade would require evidence that Kamada’s products are winning tenders or prescriptions at meaningful scale.